Tempest Therapeutics, Inc.
TPST
$10.03
$0.6757.22%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.35% | -8.94% | -4.65% | 26.28% | 22.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.86% | 37.15% | 85.23% | 60.06% | 28.27% |
| Operating Income | 16.86% | -37.15% | -85.23% | -60.06% | -28.27% |
| Income Before Tax | 17.76% | -37.40% | -84.47% | -55.56% | -26.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.76% | -37.40% | -84.47% | -55.56% | -26.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.76% | -37.40% | -84.47% | -55.56% | -26.24% |
| EBIT | 16.86% | -37.15% | -85.23% | -60.06% | -28.27% |
| EBITDA | 16.21% | -37.81% | -86.69% | -60.73% | -27.62% |
| EPS Basic | 62.50% | 31.64% | 12.31% | 14.88% | 21.04% |
| Normalized Basic EPS | 62.50% | 31.64% | 12.31% | 14.88% | 21.04% |
| EPS Diluted | 62.50% | 31.64% | 12.31% | 14.88% | 21.04% |
| Normalized Diluted EPS | 62.50% | 31.64% | 12.31% | 14.88% | 21.04% |
| Average Basic Shares Outstanding | 119.28% | 101.00% | 110.35% | 82.74% | 59.87% |
| Average Diluted Shares Outstanding | 119.28% | 101.00% | 110.35% | 82.74% | 59.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |